Ayoxxa Biosystems

Ayoxxa Biosystems is a biotechnology company founded in Singapore in 2010 and headquartered in Cologne, Germany. The company develops multiplex protein-analysis technologies intended to measure numerous biomarkers simultaneously from small volumes of blood and other biological samples. Its principal technology is based on In-situ Encoded Bead-based Arrays, or IEBA, a position-encoded bead-based protein microarray system originating in research at the National University of Singapore. The underlying work began in 2006 in the bioengineering research laboratories of the National University of Singapore, where the project was led by Dieter Trau. With continued institutional support from NUS, Ayoxxa Living Health Technologies Pte. Ltd. was established in 2010. The company received an exclusive licence to intellectual property developed at NUS and was created to advance the technology toward commercial research applications. Ayoxxa expanded into Europe in 2012 by establishing its German headquarters in Cologne under the name Ayoxxa Biosystems GmbH. From Germany, it pursued research, partnerships, services and commercialization while continuing to develop the protein-chip platform. The technology is designed to provide a large number of protein measurements from samples as small as approximately three microlitres, contrasting with conventional single-analyte assays such as ELISA, which generally require separate tests for different targets. The IEBA approach uses sets of microspheres carrying capture molecules such as antibodies. The beads are randomly distributed into microscopic cavities, and their locations are recorded to create a decoding map. After a sample is applied, target proteins bind to their corresponding capture molecules. A fluorescent detection process and imaging system then allow software to identify the bead positions and quantify the detected analytes. The platform is intended to generate very high-density data while remaining compatible with familiar immunoassay workflows, fluorescence microscopy and laboratory automation systems. Ayoxxa has positioned the technology primarily for biomedical research in academic institutions, pharmaceutical and biotechnology companies, and clinical research environments. Potential application areas described for the platform include cancer research, allergy research, cardiovascular disease, infectious diseases and age-related macular degeneration. Longer-term applications have included drug screening, biomarker discovery and preclinical diagnostic development, although the available reference material does not establish that the platform is an approved clinical diagnostic product. The company has attracted financing and backing from a number of venture, public-sector and individual investors. Named shareholders and financing participants have included Wellington Partners, NRW.Bank, High-Tech Gründerfonds, KfW, b-to-v Partners, Creathor Venture, HR Ventures and Prosnav Capital, alongside individual investors. In 2022, Ayoxxa completed a financing round led by Hong Kong-based Prosnav Capital, with the stated purpose of supporting operations and commercialization over a multi-year period. The same period marked a leadership transition from Rodney Turner to Albrecht Läufer. The company’s current operating status, ownership structure and commercial scale are not established by the supplied sources.

Ayoxxa Biosystems grew out of a research program at the National University of Singapore. In 2006, researchers in the university’s Department of Bioengineering and Department of Chemical and Biomolecular Engineering began developing a position-encoded, bead-based multiplex protein-array concept. The work was led by Dieter Trau, an assistant professor associated with those departments. The central challenge was to create a protein-analysis system capable of measuring many targets at once while using a much smaller sample volume than would be required for a series of conventional immunoassays. The resulting technology was based on In-situ Encoded Bead-based Arrays, known as IEBA. Unlike some bead-array systems that rely on physical labels to identify each bead type, IEBA records the locations of randomly distributed beads. Different bead batches carry capture molecules for different biomolecules and are applied sequentially. Software records the position of each bead and creates a decoding map. After a biological sample is introduced, the resulting antigen-antibody reactions can be read using fluorescent imaging and translated into protein measurements by analysis software. With continuing support from NUS, Ayoxxa Living Health Technologies Pte. Ltd. was founded in Singapore in 2010. The company received an exclusive licence to relevant intellectual property developed at the university and began developing the platform for commercial research use. That year it also received recognition in several entrepreneurship and innovation programs, including an award associated with the Singapore–MIT Alliance for Research and Technology and first place in the Best of Biotech business-plan competition in Austria. Ayoxxa began expanding internationally soon after its creation. In 2012, it established operations in Cologne, Germany, under the name Ayoxxa Biosystems GmbH. Cologne became the company’s headquarters and its base for further research, partnerships, services and commercialization. The company’s European presence was complemented by recognition in additional international entrepreneurship programs. In 2011, it received the Skolkovo Award in INSEAD’s 21st Business Venture Competition. In 2013, it was a runner-up in the Asian Entrepreneurship Award in Japan and received the KfW GründerChampions regional award for North Rhine-Westphalia. In 2014, it received the Promising NUS Start-up Award. The company’s product strategy centered on an open and adaptable protein-chip platform. Ayoxxa described IEBA as compatible with established bead-based assay procedures, fluorescence microscopy and automated liquid-handling equipment. The arrays were designed to support workflows ranging from small sample numbers to formats associated with 384-well screening. This approach was intended to let academic and industrial laboratories adopt multiplex protein testing without necessarily purchasing specialized flow-cytometry equipment or replacing all existing assay infrastructure. Ayoxxa’s stated application areas included biomarker research in cancer, allergy, cardiovascular disease, infectious disease and age-related macular degeneration. The platform could analyze many proteins from a small volume of blood or another bodily fluid, producing a substantially larger set of measurements than a conventional one-target-at-a-time ELISA workflow. The company emphasized research applications in academia, pharmaceutical development and biotechnology, while describing pharmaceutical screening and preclinical diagnostics as longer-term possibilities. From 2010 through 2021, the company went through multiple financing events. The supplied reference identifies a broad group of shareholders and investors, including Andreas Schmidt, Dieter Trau, Wellington Partners, NRW.Bank, High-Tech Gründerfonds, Rainer Christine, Gregor Siebenkotten, KfW, b-to-v Partners, Creathor Venture and HR Ventures. The available material does not provide reliable financing amounts or a complete capitalization history. Leadership changed in 2016, when Andreas Schmidt stepped down as chief executive. He subsequently became chief executive of Proteona, a company working in single-cell analysis and artificial intelligence, while remaining a board member of Ayoxxa. Rodney Turner became Ayoxxa’s chief executive. In 2022, Ayoxxa announced a new financing round led by Prosnav Capital of Hong Kong and said that the capital was intended to fund operations and commercialization for three to five years. Around the same time, Albrecht Läufer succeeded Turner as chief executive. The supplied sources do not establish the company’s present commercial activity, ownership, product approvals or financial performance.

1. 2022Prosnav-led financing and leadership change

   Ayoxxa closed a financing round led by Prosnav Capital and appointed Albrecht Läufer as chief executive, succeeding Rodney Turner.

   Source
2. 2016Chief executive transition

   Andreas Schmidt stepped down as CEO and Rodney Turner became chief executive; Schmidt remained a board member.

   Source
3. 2014Promising NUS Start-up Award

   Ayoxxa received the Promising NUS Start-up Award for its perceived potential to scale and create impact through its technology.

   Source
4. 2013Further entrepreneurship awards

   Ayoxxa was recognized as a runner-up in the Asian Entrepreneurship Award and received the KfW GründerChampions regional award for North Rhine-Westphalia.

   Source
5. 2012European headquarters established

   Ayoxxa expanded to Europe and established its headquarters in Cologne, Germany, as Ayoxxa Biosystems GmbH.

   Source
6. 2011Skolkovo Award

   The company received the Skolkovo Award in INSEAD’s 21st Business Venture Competition.

   Source
7. 2010Ayoxxa is founded in Singapore

   Ayoxxa Living Health Technologies Pte. Ltd. was founded with support from NUS and received an exclusive licence to relevant university-developed intellectual property.

   Source
8. 2010Early entrepreneurship recognition

   Ayoxxa received the SMART Singapore–MIT Alliance of Research and Technology Innovation Award and won the Best of Biotech global life-sciences business-plan competition.

   Source
9. 2008Proof-of-concept grant

   The project received a proof-of-concept grant from Singapore’s National Research Foundation.

   Source
10. 2006Initial IEBA technology development begins

    Researchers at the National University of Singapore began developing the position-encoded, bead-based multiplex protein-array technology that later became the foundation of Ayoxxa’s platform.

    Source

Ayoxxa positions its technology as an open, adaptable and high-multiplex alternative to conventional single-analyte immunoassays. Its platform is designed to combine high analyte density and low sample consumption with established laboratory workflows, fluorescence imaging and automated liquid handling. The primary audience is biomedical research rather than established consumer healthcare or confirmed clinical diagnostics.

• IEBA protein-chip platformMultiplex protein analysis

  Ayoxxa’s principal platform uses In-situ Encoded Bead-based Arrays to measure many protein biomarkers in parallel. Antibody-coated microspheres are distributed into microscopic cavities, their positions are recorded, and fluorescent assay signals are decoded by software. The system is intended to work with very small biological samples and to provide substantially more analyte measurements per assay than conventional single-target immunoassays.

• Ayoxxa protein microarraysProtein microarray

  The company’s silicon-based microarray format contains multiple assay wells, each incorporating large numbers of microscopic bead-containing sites. It is designed to detect protein markers associated with areas such as cancer, allergies, cardiovascular conditions, infectious diseases and age-related macular degeneration. Readout uses fluorescence microscopy and digital image analysis.

• Biomarker assay and analysis solutionsResearch-use assay system

  Ayoxxa’s technology can be configured for different biomarker panels and research questions. Its stated applications include academic biomedical research, pharmaceutical and biotechnology research, biomarker discovery, high-throughput screening and preclinical investigation. The reference material does not identify a definitive catalog of separately branded assay kits or confirm regulatory approval for clinical diagnostic use.

• 2022Raise Prosnav Capital financingM&A

  Ayoxxa stated that additional capital was needed to support operations and commercialization over the following three to five years.

  What changed. The company closed a financing round led by Hong Kong-based Prosnav Capital.

  Aftermath. The financing was associated with continued commercialization plans, but the supplied sources do not disclose the transaction value or later operating outcome.

  Source
• 2012Establish a European operating base in CologneStrategy

  After being founded in Singapore, Ayoxxa sought a European base for research, partnerships, services and commercialization.

  What changed. The company established Ayoxxa Biosystems GmbH and headquartered its European operations in Cologne, Germany.

  Aftermath. Cologne became the company’s stated headquarters and a center for further platform development and commercial activity.

  Source

• 2022Ayoxxa completes financing round led by Prosnav Capital

  Ayoxxa closed a financing round led by Hong Kong-based Prosnav Capital. The company said the funding was intended to support operations and commercialization over a projected three-to-five-year period.

  M&A
  Source
• 2022Albrecht Läufer succeeds Rodney Turner as chief executive

  Ayoxxa changed chief executives, with Albrecht Läufer succeeding Rodney Turner during the period of the new financing and planned commercialization activity.

  Leadership change
  Source

1. Ayoxxa Biosystems